What is Respiree?
Respiree operates at the intersection of artificial intelligence and clinical medicine, specializing in the development of sophisticated tools for tracking disease progression. Its flagship 1Bio platform utilizes US-patented, FDA-cleared sensors to provide longitudinal data, offering clinicians unprecedented visibility into patient health trajectories. By synthesizing complex data streams from EHR systems, the company enables more precise, data-driven interventions. This technological framework is designed to support the entire healthcare continuum, moving beyond reactive care toward a proactive, predictive model of patient management. With a robust presence in multiple global markets, Respiree is effectively bridging the gap between raw clinical data and actionable medical insights.
How much funding has Respiree raised?
Respiree has raised a total of $11.6M across 1 funding round:
Series A
$11.6M
Series A (2025): $11.6M with participation from She1K, Greenwillow Capital Management, ClavystBio, and SEEDS Capital
Key Investors in Respiree
She1K
She1K is a global network of corporate executive women that fosters innovative entrepreneurship and provides strategic backing to high-growth startups.
Greenwillow Capital Management
Greenwillow Capital Management is an asset management firm focused on early-stage technology investments and real estate across Southeast Asia.
ClavystBio
ClavystBio is a specialized life sciences investor and venture builder dedicated to translating scientific breakthroughs into impactful health solutions.
What's next for Respiree?
With the successful closure of this major strategic investment, Respiree is poised to enter a phase of aggressive operational scaling. The company intends to utilize these funds to deepen its research and development efforts, specifically focusing on enhancing the predictive capabilities of the 1Bio platform. Furthermore, the strategic backing from a diverse group of investors provides not only financial stability but also access to a vast network of expertise in life sciences and technology. As Respiree continues to expand its footprint in the U.S. and APAC regions, the focus will shift toward strengthening commercial partnerships and accelerating the adoption of its sensor-based solutions in hospital and home-care settings. This growth trajectory suggests a long-term commitment to establishing a new standard in digital health monitoring and chronic disease management.
See full Respiree company page
